Coherus Oncology (CHRS) Receivables - Net (2013 - 2026)

Coherus Oncology has disclosed Receivables - Net across 13 years of filings, most recently posting $22.1 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $22.1 million, down 63.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.1 million (down 63.52% YoY), and the FY2025 annual result was $17.8 million, down 84.0% from the prior year.
• Receivables - Net came in at $22.1 million for Q1 2026 at Coherus Oncology, up from $17.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $260.5 million in Q4 2023 to a low of $5.1 million in Q2 2025.
• The 5-year median for Receivables - Net is $111.3 million (2024), against an average of $116.1 million.
• Across the five-year window, Receivables - Net soared 148.33% in 2024 and sank 97.08% in 2025, its largest moves.
• Coherus Oncology's Receivables - Net stood at $110.0 million in 2022, then soared by 136.92% to $260.5 million in 2023, then tumbled by 57.27% to $111.3 million in 2024, then sank by 84.0% to $17.8 million in 2025, then increased by 23.85% to $22.1 million in 2026.
• The last three Receivables - Net figures came in at $22.1 million (Q1 2026), $17.8 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.